Coronavirus: Sputnik light to be India's first single dose vaccine

  • Facebook
  • Twitter
  • Reddit
  • Flipboard
  • Email
  • WhatsApp
Image tweeted by @sputnikvaccine
Image tweeted by @sputnikvaccine

New Delhi : Russia's Sputnik light can be India's first single dose vaccine against coronavirus, Dr Reddy's will have discussions with the government and the regulator in June for an instant launch, said a media report. 

"We are working very closely with our Russian partner and the Gamaleya Institute on this.  As you may be aware, the Sputnik Light has already been approved in Russia. It demonstrated an efficacy of 79.4 per cent. This is a single-shot vaccine," Deepak Sapra, the CEO of Dr Reddy's, said in an exclusive interview with NDTV.

"What it essentially is, is that it is the first shot of Sputnik," he explained, adding that a second dose would take the efficacy to up to 91.6 per cent.

"What we are doing here in India is working with our partners in Russia, getting all that data and assessing that data.  We are looking at the data on Day 28, on Day 42, both on safety and immunogenicity and we expect to have a dialogue with the Indian regulator on Sputnik Light. Assuming we are able to get this in place and get in approved in India, this would be a very, very significant aspect of India's vaccination drive because it would convert the entire vaccination process into a single vaccine which can give you 79.4% efficacy," Mr Sapra was quoted in the news report.

The launch of the vaccine will highly depend on the decision of regulators and the Central government.

For now, the two-dose Sputnik V has been imported from Russia which is fully developed and ready to be administered.

The imported vaccine shot will cost Rs 995.40 in India, Dr Reddy's Laboratories, which is manufacturing the vaccine in India, says. The price of the vaccine will come down once the production of it starts in India.

First dose of Sputnik V has been administered in Hyderabad today as a part of soft launch. Sputnik V is the third vaccine to be used in India after Serum Institute of India's Covishield and Bharat Biotech's Covaxin.